SARMs merchant accounts UK
SARMs sit in the same processing tier as research peptides and mainstream UK acquirers decline them on category. Card schemes treat SARMs as unlicensed-medicine and research-chemical risk, and Stripe, PayPal, SumUp, Square and the high-street acquirers reject or terminate on review. Specialist research-chemical acquirers underwrite SARMs on a case-by-case basis at elevated rates and reserves, with close scrutiny of how the product is presented. The legal exposure rises sharply the moment a page implies human use.
Legal status (UK)
Sold lawfully in the UK only as research chemicals labelled not for human consumption. SARMs are not approved for human use and marketing them for bodybuilding, dosing or consumption makes them unlicensed medicines under MHRA enforcement.
Best way to take SARMs payments (UK)
Our pick
MerchantHQ, specialist SARMs broker and account team
Mainstream UK acquirers (SumUp, Square, Zettle, Dojo, Worldpay, Barclaycard) decline SARMs at onboarding or terminate after launch. We hold a specialist panel of UK high-risk acquirers that underwrite it. As a broker we match you to the right one for your licence, volume and processing history, then stay on as your named UK account team for the life of the agreement.
The acquirer pays our commission on signup, so it costs you nothing on top, and we never sell your details on. We disclose the risk classification upfront so the right underwriter is approached from the start.
Get matched to a SARMs acquirerHigh-risk merchants are the most exposed to chargebacks, frozen funds and MATCH/TMF listings, and that is exactly what your MerchantHQ account team handles, for the life of the agreement.
How SARMs placements work
SARMs routes to specialist regulated-vertical acquirers matched per application rather than a published list. The right underwriter depends on your licence, volume and sub-category, so we approach it individually. We hold the relationships and disclose your risk classification upfront so the right acquirer is contacted from the start.
Typical pricing
- Rate
- 3.5% to 6.0% blended
- Settlement reserve
- 10% to 20% rolling reserve common
Watch outs
- Labelling must state research-use-only, not for human consumption; any bodybuilding, dosing or cycle guidance reclassifies the product as an unlicensed medicine.
- No performance, muscle-gain or health claims in copy, metadata or advertising.
- Mainstream processors terminate SARMs accounts on detection; a compliant specialist account avoids frozen funds.
- Underwriting reviews COA documentation, age-gating and disclaimer placement.
Director, MerchantHQ
Oliver leads MerchantHQ's terminal testing and acquirer comparison. With a background in UK commercial finance and merchant payments, he oversees terminal reviews, switching guidance and high-risk vertical mapping.
Last reviewed: 3 June 2026